Health Canada, the Canadian federal health authority, has issued a Product License to Sabinsa for a significant health claim on LactoSpore Balance: “Helps relieve abdominal pain associated with IBS (Irritable Bowel Syndrome).” The strain is LactoSpore MTCC 5856.
“This health claim was based on the IBS clinical study we did for LactoSpore,” said Shaheen Majeed, Sabinsa’s marketing director. “It gives us great validation for the clinical work we’re doing globally.”
While LactoSpore has been on the market for over 20 years, emerging clinical evidence on LactoSpore has moved the focus beyond maintaining gut health into sports nutrition, cognitive health, IBS and related gut health conditions.
Sabinsa obtained self-affirmed GRAS status for LactoSpore in the US in 2008, with LactoSpore’s intended market reach clearly listed, and included foods, beverages, chocolate, confectionaries such as gummies and soft candies, yogurts and soups. LactoSpore has also found applications in whey protein supplements, a staple of the sports nutrition market. Earlier in 2016, US-FDA submitted their no questions GRAS letter for Sabinsa’s LactoSpore as well.
A number of Sabinsa ingredients have Canadian Masterfiles, such as BioPerine, Curcumin C3 Complex, Curcumin C3 Reduct, LactoSpore and ForsLean, all available for Letter of Access requests.
Sabinsa Corporation received a Foreign Site Registration Number for its Payson, UT, finished product manufacturing facility from Health Canada’s Natural and Non Prescription Health Product Directorate (NNHPD) in August 2015.